You're listening to this week in cardiology from the heart.org on medscape.

You can now access the latest in medical news on your Amazon Alexa enabled device.

Join me, Perry Wilson, every weekday morning for Medscape Medical Minute,

where I highlight the top medical stories of the day.

To add Medscape Medical Minute to your flash briefing, search for Medscape Medical

Minute on Amazon and click enable. Or open the Amazon Alexa app, go to Skills, search for Medscape

Medical Minute and click enable. Then say,

Alexa, what's the news or Alexa, what's my flash briefing? I hope you'll join us.

Hi everyone, this is John Mandrova from the Heart.org Medscape Cardiology, and this is this week in

cardiology for October 23rd, 2020.

This week, the lessons of Tosaizumab, hyper trophic cardiomyopathy, cerebralads, and surrogate

endpoints. To start with COVID, in weeks past I have said it was still bad.

This week, I will say it is worse.

Hospitalizations are definitely worse now.

But COVID Science this week offered up a huge lesson on critical

appraisal of evidence. The IL6 blocker Tosaizumab has been proposed as a

treatment for COVID-19 and it makes perfect sense is a reported a large multi-centered cohort study and included 4,000 patients with COVID-19

and a study question was is Tosolizamab associated with reduced mortality. Looking back the author's is a

Mab associated with reduced mortality. Looking back, the authors compared about 430

patients who received a drug and 3,500 patients who did not.

And of course, you know, when there's a treatment group of

433 patients and a control arm of about 3,500 patients, you know it is a

...